News - Humira, Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 28 results

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA

19-09-2013

The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

German pharma watch dog finds benefits for biologicals in RA

30-08-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined nine biotechnologically…

Anti-Arthritics/RheumaticsBiotechnologyCimziaEnbrelEuropeHumiraKineretMabTheraOrenciaPharmaceuticalPricingRegulationRemicadeRoActemraSimponi Injection

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis

20-06-2013

The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib

13-06-2013

Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study

12-06-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments

03-06-2013

Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

AbbVie's Humira cleared in EU for polyarticular juvenile idiopathic arthritis

03-04-2013

The European Commission has approved an extension of the European Union marketing authorization for US…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulation

Roche's RoActemra shows superiority to Humira in rheumatoid arthritis

18-03-2013

Over 50% of rheumatoid arthritis patients can achieve low disease activity or remission with Swiss drug…

Anti-Arthritics/RheumaticsBiotechnologyHumiraPharmaceuticalResearchRoActemraRoche

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency

11-03-2013

Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

Positive Ph III results for AbbVie's Humira in pediatric Crohn's disease; five leukemia studies suspended

17-02-2013

AbbVie (NYSE: ABBV), the new spin-out from Abbott Laboratories, has announced the first long-term, patient-reported…

Abbott LaboratoriesAbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraOncologyPharmaceuticalResearch

Steady sales for MAbs in rheumatoid arthritis - can biologics beat the patent cliff?

13-02-2013

Since 2004, the market for monoclonal antibodies (MAbs) in rheumatoid arthritis (RA) has experienced…

Anti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingPharmaceuticalRemicade

Global rheumatology market controlled by Enbrel, Humira and Remicade

24-12-2012

The global rheumatology therapeutics market has been forecast to increase at a compound annual growth…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyCelebrexEnbrelGlaxoSmithKlineGlobalHumiraMarkets & MarketingPfizerPharmaceuticalRemicadeTakeda PharmaceuticalsUloric

Biosimilars threaten to burst Humira's blockbuster bubble

29-11-2012

US health care major Abbott Laboratories' (NYSE: ABT) Humira (adalimumab) has a strong reputation as…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGenericsHumiraMarkets & Marketing

Abbott presents new Humira data at ACR

12-11-2012

US pharma major Abbott Laboratories (NYSE: ABT) today announced results from a post-hoc analysis of its…

Abbott LaboratoriesAnti-Arthritics/RheumaticsHumiraPharmaceuticalResearch

AET BioTech and BioXpress to co-develop biosimilar Humira

02-11-2012

Plans to develop another biosimilar version of Abbott Laboratories blockbuster rheumatoid arthritis drug…

Abbott LaboratoriesadalimumabAET BioTechAnti-Arthritics/RheumaticsBiotechnologyBioXpress TherapeuticsGenericsHumiraProductionResearch

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA

07-10-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) announced on Friday that the European Commission has granted…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEnbrelEuropeHumiraMarkets & MarketingNorth AmericaOrenciaPfizerPharmaceuticalRegulation

Abbott's Humira cleared for Crohn's disease in EU

31-08-2012

The European Commission has approved US health care major Abbott Laboratories' (NYSE: ABT) blockbuster…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyEuropeGastro-intestinalsHumiraPharmaceuticalRegulation

Abbott's Humira gains FDA panel backing for wider use

29-08-2012

The US Food and Drug Administration's Gastrointestinal Drugs Advisory Committee yesterday voted by 15…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

Abbott/Eisai's Humira has emerged as leading psoriasis agent

07-08-2012

For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

Added European indications for Abbott's Humira and Novartis' Afinitor

30-07-2012

US health care major Abbott Laboratories (NYSE: ABT) today announced that the European Commission (EC)…

Abbott LaboratoriesAfinitorAnti-Arthritics/RheumaticsEuropeHumiraNovartisOncologyPharmaceuticalRegulation

Roche's RoActemra beats leading rival Humira in RA study; other news from EULAR

07-06-2012

Swiss drug major Roche (ROG: SIX) yesterday released new data from the ADACTA study which showed that…

Abbott LaboratoriesAnti-Arthritics/RheumaticsHumiraPharmaceuticalResearchRoActemraRoche

US rheumatologists continue to increase use of biologics for RA treatment

29-03-2012

Biologic agents remain the preferred treatment for patients suffering from rheumatoid arthritis (RA),…

ActemraAnti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingNorth AmericaOrenciaPharmaceuticalRituxantofacitinib

1 to 25 of 28 results

Back to top